SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending due to its strong community and growing holder count, signaling increasing interest and conviction. The community is actively discussing the potential for a major rally, driven by the expectation of a significant move in the dawg coin sector. Many believe $KENDU.X is undervalued and primed for substantial growth, emphasizing its real-world applications and brand development.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as the community rallies around its position as the first meme coin on Bitcoin, emphasizing its fair launch and strong community-driven growth. Discussion highlights its unique utility in strengthening the Bitcoin network through miner fees, setting it apart from other meme coins. Some believe $DOG.X has the potential to outperform other meme coins like $DOGE.X.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses potential catalysts, including speculation around a Dogecoin ETF and its impact on price. Sentiment is focused on the potential for significant gains, with some looking toward the token reaching the $1 mark. The conversation also includes discussion around Dogecoin's relationship with other meme coins and their respective ecosystems.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending due to positive updated Phase 3 HARMONi data for its lung cancer drug, ivonescimab, sparking optimism about its potential. The community is focused on the drug's OS benefit and its competitive efficacy compared to existing treatments, while also debating the validity and interpretation of trial data. Some investors are speculating about a potential acquisition or partnership, particularly with AstraZeneca, driving further interest in the stock.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the Bitcoin memecoin gains traction within the crypto community, with many touting its fair launch and strong community backing. Conversation highlights its potential to become the meme face of Bitcoin and draw comparisons to other popular memecoins. Community members are emphasizing its organic growth and decentralized nature.

DOVU

DOVU.X is trending as the community highlights its staking rewards and potential in the Real World Asset (RWA) space, particularly due to its "Trust Operating System." Recent news around partnerships and deals related to carbon credits and ecological projects may be acting as a catalyst. Community members are actively discussing its association with Hedera and potential for significant growth.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending as traders discuss its recent listing on Coinbase and potential for high gains, with some community members pointing to its AI-powered trading platform and the possibility of new partnerships. Bullish sentiment is fueled by the hope of 'dropping zeros' and achieving significant market cap growth. Others are comparing it to similar tokens that have experienced substantial pumps.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a recent land sale agreement, potentially boosting its NAV, which has captured the attention of traders. The stock's low float is fueling discussions of a potential squeeze, with community members actively watching for breakout levels. Some are betting on a significant upward move, drawing comparisons to other low-float runners.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco ($CCJ) is trending amid renewed interest in nuclear energy, potentially driven by Trump administration executive orders and the increasing power demands of AI data centers. Community discussions highlight analyst upgrades, strong technical setups, and potential benefits from Westinghouse holdings, while also noting overbought conditions and potential pullbacks. Some investors are favoring US-based uranium companies like $UEC due to potential domestic policy tailwinds.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid speculation of a potential buyout or strategic partnership, fueled by recent executive changes and ongoing negotiations. The community is closely watching for news related to deal structures and milestones, while also considering the possibility of a short squeeze due to high short interest and limited share availability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of UroGen Pharma gained momentum after the U.S. FDA approved Zusduri, a therapy for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, prompting a flurry of bullish analyst revisions and heightened interest from retail investors.UroGen Pharma shares jumped 8.6% to $12.03 on Friday, hitting a three-month high, and edged up further to $12.06 in after-hours trading.Goldman SachsGoldman Sachs raised its price target to $16 from $3, noting the stock’s 22% post-approval rally surprised most investors, given the negative ODAC vote and briefing document that had flagged an unfavorable benefit-risk profile.&nbsp;In a note, analyst Paul Choi reminded investors that FDA approvals following negative oncology advisory panels are “exceedingly rare.”&nbsp;The firm remains ‘Neutral’ on the stock despite the unexpected regulatory success.OppenheimerOppenheimer raised its target to $31 from $10, reiterating an ‘Outperform’ rating and emphasizing a key update from Friday’s conference call—a $21,500 per-dose list price for Zusduri.&nbsp;Analyst Leland Gershell expects clarity on UGN-103's path to approval will help preserve franchise exclusivity beyond 2031, adding that sales could reach $1 billion over time.&nbsp;He also said he would “take advantage of any near-term weakness to buy UroGen shares.”ScotiabankScotiabank lifted its target to $47 from $23, increasing its FDA approval probability from 60% to 100%.&nbsp;The firm continues to rate the stock ‘Outperform,’ citing a $1 billion peak market opportunity for Zusduri and revising valuation models accordingly.<a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">Guggenheim and D. Boral</a> also reaffirmed bullish views on UroGen Pharma, calling the FDA's early approval of Zusduri a 'surprise decision' that bypassed further trial requirements and validated regulatory flexibility in high-unmet-need cancer settings.The drug, a combination of mitomycin and sterile hydrogel, is administered once weekly for six weeks via catheter, offering a non-surgical alternative to transurethral resection of bladder tumors, the current standard of care.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The stock has risen 12.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri

UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.

Equity

Shares of UroGen Pharma (URGN) shot up 9% on Friday morning after Guggenheim hiked its price target on the stock on the heels of the U.S. Food and Drug Administration approving its Zusduri medication.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.urogen.com/news-releases/news-release-details/us-fda-approves-urogens-zusduritm-mitomycin-intravesical">approved</a> Zusduri for adults with a type of cancer of the lining of the bladder called recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) on Thursday. Zusduri consists of mitomycin and sterile hydrogel and is designed for potent tumor ablation.Patients can receive their Zusduri dose from a healthcare provider once a week for 6 weeks into the bladder through a urinary catheter, as opposed to the existing standard of care which is a surgical procedure called transurethral resection of bladder tumor.Guggenheim subsequently raised the firm's price target on UroGen Pharma to $30 from $15 while keeping a ‘Buy’ rating on the shares.The new price target implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.The FDA approval for Zusduri, a day ahead of the deadline, is "a surprise decision" following the negative Oncologic Drug Advisory Committee (ODAC) vote during an FDA advisory committee meeting last month, the analyst told investors, as per TheFly.Last month, the ODAC committee narrowly voted against its benefit/risk profile, effectively ending hopes for approval as the FDA considers independent advice from the committee.The firm believes this outcome represents a best-case scenario for UroGen, given that the marketing approval indicates a broad indication of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, without the need to conduct another large randomized controlled trial and "only minor safety warnings."D. Boral Capital analyst Jason Kolbert, meanwhile, reiterated a ‘Buy’ rating and $25 price target on UroGen Pharma. The approval validates the FDA's willingness to exercise flexibility in high-unmet-need indications, despite divided advisory input, the analyst said.Zusduri is expected to be available in the U.S. on or around July 1, 2025, for the treatment of adults with recurrent LG-IR-NMIBC. LG-IR-NMIBC affects approximately 82,000 people in the U.S. each year, and of those, an estimated 59,000 are recurrent cases.On Stocktwits, retail sentiment around UroGen rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1274/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_9_30_23_AM_png_01d194b268.webp" alt="URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1274" height="136"><figcaption>URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism that the stock would reach $20.<stembedurl>https://stocktwits.com/TarriffKing007/message/617822498</stembedurl><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is up approximately 13% this year but down by 31% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-inks-5.3-billion-deal-with-cspc-pharma-for-new-drug-candidates/chli5sARRbG">AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20

The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.

Shares of biotech company UroGen Pharma Ltd. (URGN) plummeted 48% on Wednesday noon after the company said that a committee of the U.S. Food and Drug Administration (FDA) voted in opposition to a favorable benefit-risk profile for its investigational drug UGN-102, an intravesical solution for the treatment of a recurrent form of bladder cancer.CEO Liz Barrett <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250521737507/en/UroGen-Announces-Outcome-of-Oncologic-Drugs-Advisory-Committee-for-UGN-102-for-the-Treatment-of-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC">said</a> the company is "disappointed" by the outcome of the meeting of FDA’s Oncologic Drugs Advisory Committee (ODAC), but added that the company believes in the clinical data in support of the drug.Low-grade intermediate-risk nonmuscle-invasive bladder cancer has no FDA-approved therapies, the CEO said, while adding that it is looking forward to working with the FDA as they complete their review of its new drug application (NDA).The FDA considers independent advice from ODAC, which weighs down the possibility of approval. The FDA is expected to conclude its review of the application by June 13.UGN-102 for intravesical solution is an innovative drug formulation of mitomycin, an antibiotic used as a drug in cancer treatment. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.The company said the adverse impacts identified with the treatment in its late-stage trial, such as urine retention, are typically manageable in routine urologic practice. &nbsp;UroGen submitted its NDA to the FDA in August 2024. If approved in June, the company initially said it would make the product available in July.On Stocktwits, retail sentiment around UroGen remained unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume stayed put at ‘extremely high’ levels. &nbsp;<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_21_at_1_58_13_PM_png_0f90b9f92d.webp" alt="URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is down by about 64% this year and nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/shopify-bets-on-gen-ai-with-new-ai-tools-to-simplify-store-creation-but-stock-drops/ch0eOwYRbYo">Shopify Bets On Gen-AI With New AI Tools To Simplify Store Creation But Stock Drops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled

The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13.

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will...

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its...

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the...

UroGen Pharma to Present at Upcoming Investor Conferences

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month...

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of...

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

URGN
UroGen Pharma Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest URGN News

URGN UroGen Pharma Ltd